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Role of thromboxane A2 and prostacyclin in uninephrectomy-induced
attenuation of ischemic renal injury. Contralateral uninephrectomy atten-
uates unilateral renal ischemic injury. The present work was performed to
elucidate whether the beneficial effect of uninephrectomy was mediated
through the modification of the actions of thromboxane A2 (TxA2) or
prostacyclin. Unilateral ischemic injury was provoked by a 60-minute left
renal artery occlusion in right nephrectomized (Nx) and in sham-nephrec-
tomized (Sham-Nx) rats. Inulin clearance (C1) of left kidney 48 hours
after ischemia was significantly higher in the Nx group than in the
Sham-Nx group (0.11 0.07 vs. 0.00 0.00 mI/mm/kidney, P < 0.05).
Ischemia-induced tubular necrosis was also less in Nx animals. Proliferat-
ing cell nuclear antigen (PCNA) staining, a marker for cell proliferation,
was found more markedly in Nx rats than in Sham-Nx animals. Forty-eight
hours after ischemia, renal cortical TxB2 content was greater in Sham-Nx
rats than in Nx rats (29.5 4.4vs. 18.3 1.7 pg/mg protein, P < 0.05). No
significant difference was found in the intrarenal content of 6-keto
prostaglandin F1 between two ischemia groups. A thromboxane syn-
thetase inhibitor, OKY-046 (100 mg/kg/day, i.p.), significantly increased
C1,, 48 hours after ischemia (0.00 0.00 vs. 0.17 0.09 mI/mm/kidney,P < 0.05) and attenuated ischemic tubular damage in Sham-Nx rats but
not in Nx animals. Under OKY-046 treatment, no significant difference
was found in postischemic C1,, and ischemic tubular damage between the
Nx and Sham-Nx groups. OKY-046 also increased PCNA expression in
the cortex and outer stripe in Sham-Nx animals. These data suggest that
less production of intrarenal TxB2 plays an important role for the
uninephrectomy-induced attenuation of ischemic renal damage and for
the facilitation of tubular recovery.
A number of investigations have demonstrated that contralat-
eral uninephrectomy attenuates the unilateral ischemic renal
injury [1—6]. The mechanisms for this beneficial effect of unine-
phrectomy, however, have not been established. Fried et al [41
suggested that the changes in the environmental milieu that
occurs when all functioning tissue is made ischemic are important
in the protective effect of uninephrectomy. A somewhat similar
modulation of renal function by the absence or the presence of
intact kidney was reported in rats with ureteral obstruction. The
urine volume and glomerular filtration rate (GFR) after the
release of ureteral obstruction was greater in rats with bilateral
ureteral obstruction than rats with unilateral ureteral obstruction
[7, 8]. The higher urine volume and GFR in rats with bilateral
ureteral obstruction were associated with the less intrarenal
production of thromboxane B2 (TxB2) and higher production of
prostacyclin [8]. These findings suggested that the production of
intrinsic arachidonic acid metabplites in the obstructed kidney is
modified by the presence or the absence of a healthy kidney, and
that the divergent responses in the production of these vasoactive
substances might modulate the postobstructed changes in renal
function.
Recent studies have shown that renal ischemia resulted in
increases in TxB2 and 6-keto PGF1, production [9—14], and that
the modulation of the actions of these substances [9—11] or the
treatment with prostacyclin [15, 16] attenuated the ischemic renal
injury. However, little information is available whether the pro-
duction of these vasoactive substances in ischemic insult are
modified by the absence of a healthy kidney. In this experiment,
we measured intrarenal concentrations of TxB2 and 6-keto PGF1,
after the unilateral renal ischemia in uninephrectomized (Nx) and
sham-nephrectomized (Sham-Nx) rats. Having demonstrated that
contralateral uninephrectomy suppressed the ischemia-induced
increase in renal TxB2 concentration, we then evaluated the effect
of a thromboxane A2 synthetase inhibitor, OKY-046, on ischemic
renal injury in both Nx and Sham-Nx animals to evaluate whether
the lesser increase in renal TxB2 content contributes to the
beneficial effect of uninephrectomy.
Methods
Induction of ischemic renal injury
Experiments were performed on 104 male Sprague-Dawley rats
weighing 220 to 320 g and allowed free access to standard rat chow
and drinking water. Each animal underwent either sham or right
nephrectomy under pentobarbital anesthesia (50 mg/kg, i.p.)
through a midline incision. Just after nephrectomy or sham-
nephrectomy, a 60-minute left renal artery occlusion (RAO) or
sham occlusion (Sham-RAO) was performed using vascular clamp
in each rat. Rats were divided into four groups by these proce-
dures: grOup 1, Sham-Nx plus Sham-RAO; group 2, Sham-Nx plus
RAO; group 3, Nx plus Sham-RAO; group 4, Nx plus RAO.
Following the release of the occlusion, the animal's abdomen was
sutured and the animal returned to its cage.
Measurements of renal contents of TxB2 and 6-keto PGFJ,,
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Forty-eight hours after the release of RAO, 30 rats (group 1, 8;
group 2, 7; group 3, 8; group 4, 7) were anesthetized with
pentobarbital (50 mg/kg) and were served for the measurements
of renal contents of 6-keto PGF1,,, and TxB2. The kidney was
rapidly perfused with chilled 0.9% saline containing EDTA (10
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mM) and indomethacin (0.1 mM) to remove intravascular blood.
Then cortical portion was excised and stored at —80°C. On
measurements, kidney tissue was homogenized in 2 ml of 95%
ethanol at 4°C and then centrifuged at 600 g for 10 minutes. The
supernatant was used for measurements of arachidonic acid
metabolites by RIA methods (1251-thromboxane B2 and 12516
keto PGF kit, Daiichi RI, Japan). The tissue protein content
was measured with Lowry's method [17]. To estimate urinary
excretion of TxB2, urine was collected for 12 hours through the
left ureter catheter in restricted cages using other 19 rats (group
1, 6; group 2, 6; group 4, 7). Urinary excretion of TxB2 was
expressed as the ratio to urinary creatinine excretion.
Effect of OKY-046 on ischemic renal injury
To evaluate the contribution of intrarenal TxB2 to postischemic
injury in Nx and Sham-Nx rats, the effect of a thromboxane A2
synthetase inhibitor, OKY-046, on postischemic renal injury was
examined in 55 rats (group 1, 14; group 2, 13; group 3, 13; group
4, 15). Six to seven rats per each group were treated with the
intraperitoneal administration of OKY-046 (50 mg/kg) twice a day
from 24 hours before RAO or Sham-RAO to the end of studies.
Twenty-five mg/kg of OKY-046 is known to be enough to inhibit
intrarenal TxA2 biosynthesis in normal rats [18]. The present dose
of 100 mg/kg/day is equivalent to the doses previously reported to
inhibit intrarenal TxA2 production following glycerol injection
[18] or renal allograft [19]. The other 6 to 8 rats per each group
were treated with vehicle (0.5 ml of 0.9% saline).
Clearance studies
Forty-eight hours after RAO or Sham-RAO, clearance studies
were performed in the left kidney under pentobarbital sodium
anesthesia (50 mg/kg). A tracheostomy tube and jugular vein and
carotid artery catheter were inserted. 14C-inulin saline solution (1
pCi/ml) was infused at 20 xl/min through the jugular vein
catheter. The carotid artery was used for blood pressure monitor-
ing and blood sampling. Blood pressure was measured with a
pressure transducer (MPU 05A; Nihon Kohden, Tokyo, Japan).
Renal blood flow (RBF) was measured with electromagnetic
flowmeter (MFV-1200; Nihon Kohden) by placing a flow probe
(FJ-OO7TS, 00.7 mm; Nihon Kohden) on the left renal artery. The
left ureter catheter was cannulated for urine sampling. After a
40-minute equilibration period, two 10-minute clearance studies
were performed. In the measurement of 14C-inulin in blood and
urine, each sample was added to 10 ml of ACSR II (Amersham,
Canada) and its radioactivity was determined in a liquid scintilla-
tion counter (LS-5000TS, Beckman). The values of inulin clear-
ance (C1,,) were expressed as the mean of those in two clearance
periods. Since uninephrectomy induces increases in RBF and C1,,
of the left kidney at 48 hours after nephrectomy, data are
expressed as percent of respective controls. After the completion
of clearance studies, the left kidney was removed for histological
and immunohistochemical examinations.
Histological examination
Kidney tissue was fixed in 10% neutral buffered formalin
solution, dehydrated in graded alcohols, and embedded in paraf-
fin. The kidney block tissue was cut at 3 tm and stained with
periodic acid-Schiff reagents. A semiquantitative analysis of the
histological damage by light microscope was then carried out
according to the previous report [20]. One hundred randomly
selected tubules in the cortex and outer stripe and inner stripe of
outer medulla were scored in 5 to 6 rats per each RAO group. The
criteria were as follows: 0, normal; 1, areas of tubular epithelial
vacuolar degeneration, necrosis, and desquamation involving <
25%; 2, similar changes involving > 25% but < 50%; 3, similar
changes involving > 50% but < 75%; 4, similar changes involving
> 75%. In addition, the number of intratubular casts per one field
was counted at x400 magnification in cortex and outer medulla
for each rat. The mean score for histological damage or the mean
number of intratubular casts in cortex and outer medulla were
calculated for each rat, and the means SEM were then calculated
for each group. To minimize observer bias, the morphometric
examinations were performed without any knowledge of the
group from which the tissue came and in a coded fashion.
Proliferating cell nuclear antigen (PCNA) expression
PCNA expression was analyzed immunohistochemically in
postischemic kidneys. The kidney sections were mounted on
poly-L-lysine-coated slides and redehydrated after deparaffiniza-
tion. After equilibration in phosphate buffered solution, kidney
sections were incubated for 15 minutes with 3% hydrogen perox-
ide to consume endogenous peroxidase, and then incubated for 10
minutes with 10% normal horse serum. Sections were incubated
with a monoclonal antibody to PCNA (Oncogene Science, USA)
at 1:50 dilution for 30 minutes, followed by a universal biotiny-
lated anti-mouse-immunoglobulin (Nichirei, Tokyo, Japan) for 10
minutes and streptoavidin peroxidase (Nichirei) for 5 minutes at
room temperature. Antibody localization was performed using the
peroxidase reaction with 3,3'-diaminobenzidine tetrahydrochlo-
ride (Sigma, St. Louis, MO, USA). Slides were counterstained
with hematoxylin-eosin and mounted with permount. A semi-
quantitative analysis of PCNA staining was then carried out in a
blind fashion. One hundred randomly selected tubules in the
cortex and outer stripe and inner stripe of outer medulla were
scored in 5 to 6 rats per each RAO group. The criteria were as
follows: 1, the number of positively PCNA staining nuclei per one
tubule was 0—1; 2, the number was 2—3; 3, the number was 4—5; 4,
the number was above 6. The mean score for PCNA staining were
calculated for each rat, and the means SEM were then calculated
for each group.
Statistical analysis
All data are expressed as means SCM. For comparisons of the
data from multiple groups, one-way analysis of variance was used.
Results
Renal contents of TxB2 and 6-keto PGFJ,,
Contralateral uninephrectomy induced a significant decrease in
renal cortical TxB2 content compared to Sham-Nx rats (10.8 1,8
vs. 16.3 1.2 pg/mg protein, P < 0.05), but no significant change
in renal cortical 6-keto PGF1, (Fig. 1). Renal ischemia provoked
significant increases in cortical TxB2 and 6-keto PGF1,, contents in
Sham-Nx and Nx groups (Fig. 1). The renal cortical TxB2 contents
after ischemia was greater in Sham-Nx rats than in Nx animals
(29.5 4.4 vs. 18.3 1.7 pg/mg protein, P < 0.05), but no
significant difference was found in 6-keto PGF1 content between
two ischemic groups. The ratio of 6-keto PGF1JTxB2 level
following renal ischemia was lower in the Sham-Nx group than in
the Nx group before (1.57 0.10 vs. 2.54 0.11, P < 0.01) and
Kato et al: Thromboxane in postischemic ARF 1579
after (1.23 0.25 vs. 2.00 0.19, P < 0.05) renal ischemia.
Urinary TxB2 excretion in the postischemic kidney was markedly
higher in the Sham-Nx group than in the Nx group (7.4 1.7 vs.
1.4 0.2 nglmg creatinine; P < 0.01), and both of these were
significantly higher than that in the nonischemic kidney (group 1;
0.8 0.1 nglmg creatinine).
Effect of OKY-046 on postischemic injury
There was no significant difference in body weight and mean
arterial pressure among all studied groups (Table 1).
In vehicle-treated rat without RAO, urine volume, RBF and
C1, were greater in the Nx group when compared with the
Sham-Nx group. A 60-minute RAO induced oliguria in Sham-Nx
rats but did not in Nx rats. The C1. and RBF after ischemia were
significantly greater in Nx rats than in Sham-Nx animals (P <
0.05). Percent recovery of C1,, 48 hours following ischemia was
significantly higher in the Nx group than in the Sham-Nx group
(7.0 4.7 vs. 0.0 0.0%, P < 0.05; Fig. 2).
The administration of OKY-046 did not affect renal hemody-
namics in Sham-Nx and Nx groups without RAO (Table 1). In
contrast, the treatment with OKY-046 significantly increased
urine volume in postischemic kidney in both Sham-Nx and Nx
groups (groups 2 and 4). The administration of OKY-046 pro-
voked significant increases in RBF and C1,. in Sham-Nx rats
(Table 1). In contrast, in Nx rats, no significant difference in RBF
and C1, after ischemia was found between vehicle-treated and
OKY-046 treated groups (Table 1). The percent recoveries of
RBF and Cth were also facilitated in Sham-Nx rats but not in Nx
animals. Under the treatment with OKY-046, no significant
difference was found in % recovery of C1, between Nx and
Sham-Nx groups (Fig. 2).
Histological examination
Light microscopic observation revealed extensive tubular ne-
crosis and cast formation in the cortex and outer stripe and inner
stripe of outer medulla in vehicle-treated ischemic kidneys (Table
2). The ischemia-induced tubular necrosis was significantly less in
Nx rats than in Sham-Nx animals. Treatment with OKY-046
resulted in significant decreases in tubular necrosis and cast
formation in the Sham-Nx group. In the Nx group, the treatment
with OKY-046 significantly reduced the numbers of cast forma-
tion in cortex and inner stripe, but did not decrease the mean
score of tubular necrosis. The mean scores of tubular necrosis
were the same between Sham-Nx and Nx groups following
OKY-046 treatment (Table 2).
PCNA staining
Normal kidneys showed only occasional PCNA positive nuclei
in proximal tubular cells (data are not shown). Forty-eight hours
after ischemia, a large number of tubular cell nuclei were PCNA
positive in the cortex and outer medulla. PCNA expression in the
outer stripe was significantly greater in Nx rats than in Sham-Nx
animals (Table 3). Following the administration of OKY-046, the
ischemia-induced increase in PCNA staining was more prominent
in Sham-Nx group but not in Nx group. Under OKY-046 treat-
ment, the number of PCNA positive nuclei was rather greater in
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Fig. 1. Intrarenal (A) TxB2 and (B) 6-keto PGF1,, contents. Uninephrectomy decreased cortical TxB2 content, and a 60-minute renal artery occlusion
(RAO) provoked increases in intrarenal TxB2 and 6-keto PGF1,, levels 48 hours after RAO. The TxB2 content after RAO was significantly less in Nx
rats than Sham-Nx animals (* P < 0.05, **P < 0.01).
Nx Nx
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1 8 279 21 157 7 4.0 0.8 4.3 0.5 1.08 0.15
2 6 273 12 157 7 0.007 0.004 3.2 0.2 0.00 0.00
3 6 282 18 152 7 8.8 2.7 8.1 0.7 1.59 0.15
4 8 274 11 157 8 5.2 0.6 5.3 0.4 0.11 0.07
P values



























3 7 269 14 155 6 7.5 0.8 7.5 0.8 1.50 0.10
4 7 293 12 157 6 9.9 1.9 5.0 0.4 0.20 0.09
P values












Data are means SEM. Group 1, sham nephrectomy (Sham-Nx); Group 2, Sham-Nx plus renal artery occlusion (RAO); Group 3, Nephrectomy (Nx);
Group 4, Nx plus RAO. Abbreviations are: MAP, mean arterial pressure; RBF, renal blood flow; C1, inulin clearance; and NS, not significant.
a P < 0.05, as compared with vehicle-treated group











In the present work, the decrease in C1 induced by unilateral
renal artery occlusion was significantly ameliorated by the re-
moval of contralateral kidney, supporting the previous reports
[1—6]. The mechanisms for this beneficial effect of uninephrec-
tomy have not been established.
Recently, the contributions of intrinsic TxA2 and prostacyclin to
the development of ischemic renal injury have been suggested.
For example, plasma and/or renal contents of TxB2 and 6-keto
PGF1,, increased after renal ischemia [9—14]. Pretreatment with
OKY-046 prevented ischemic injury 24 hours after a 45-minute
renal artery clamping in rats [9, 11]. Pharmacological interven-
tions with TxA2 receptor antagonist [10, 21] and prostacyclin [15,
16] also alleviated ischemic renal failure. These findings suggested
that TxA2 and prostacyclin may play an important role in the
pathogenesis of ischemic renal injury, and urged us to study the
role of these vasoactive substances in uninephrectomy-induced
attenuation of ischemic renal damage.
In the present study, a 60-minute renal artery occlusion induced
significant increases in renal TxB2 and 6-keto POF1, contents in
Sham-Nx and Nx animals. The renal content of TxB2 following
ischemia was higher in Sham-Nx rats than in Nx animals. Since
urinary excretion of TxB2 following ischemia was significantly
higher in Sham-Nx animals, the higher renal content of TxB2
following ischemia in Sham-Nx rats seemed to be caused by














Fig. 2. Percent recovery of (A) renal blood flow
(RBF) and (B) inulin clearance (C,,,) 48 hours
after renal artery occlusion (RAO). Following
OKY-046 treatment, % recovery of RBF
increased significantly in Sham-Nx group but
did not in Nx group. No significant difference in
C1,, 48 hours after RAO was found between
Sham-Nx and Nx groups under OKY-046
treatment. Symbols are: (D) vehicle; () OKY-
046. * P < 0.05; ** P < 0.01.
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Cortex Outer stripe Inner stripe
Necrosis Cast Necrosis Cast Necrosis Cast
Vehicle-treated groups
2 6 3.32 0.16 12.3 1.9 3.68 0.08 10.4 1.4 3.13 0.15 37.2 1.4
4 5 2.82 0.18 8.8 1.8 2.47 0.18 10.2 2.4 1.81 0.40 38.6 1.6
P values
Group 2 vs. 4 <0.05 NS <0.01 NS <0.01 NS
OKY-046-treated groups
2 5 2.45 0.26" 3.4 l1' 2.48 031b 6.6 1.Oa 2.06 024b 24.8 2.0"
4 6 2.44 0.23 1.9 0.5" 2.65 0.11 5.0 1.7 1.93 0.12 26.4 39a
P values
Group 2 vs. 4 NS NS NS NS NS NS
Values are mean SEM. Necrosis is expressed as the mean score of grading categories (from 0 to 4) in individual rats for each group (details are given
in Methods). NS, not significant. Group 2, sham nephrectomy (Sham-Nx) plus renal artery occlusion (RAO); group 4, nephrectomy (Nx) plus RAO.
a P < 0.05, as compared with respective vehicle group
b P < 0.01, as compared with respective vehicle group








2 5 1.46 0.10 1.54 0.07 1.39 0.05
4 5 1.80 0.14 1.88 0.09 1.31 0.04
P values
Group 2 vs. 4 NS <0.05 NS
OKY-046-treated
groups
2 5 1.96 0.18a 2.39 013b 1.63 0.16
4 6 1.59 0.10 1.82 0.07 1.30 0.04
P values
Group 2 vs. 4 NS <0.01 <0.05
Values are means SEM. PCNA score is expressed as the mean scale of
grading categories (from 1 to 4) in individual rats for each group (details
are given in Methods). NS, not significant. Group 2, sham nephrectomy
(Sham-Nx) plus renal artery occlusion (RAO); group 4, nephrectomy (Nx)
plus RAO.
a P < 0.05, as compared with respective vehicle group
bP < 0.01, as compared with respective vehicle group
found in renal 6-keto PGF1, content between Nx and Sham-Nx
groups 48 hours after RAO. The administration of OKY-046
significantly increased C1,, and attenuated tubular necrosis 48
hours after RAO in Sham-Nx rats but did not in Nx animals. The
differences in postischemic C,,, and tubular damage between Nx
and Sham-Nx animals were abolished by the inhibition of TxA2
production. These data suggested that the less TxA2 production
after RAO played an important role in the uninephrectomy-
induced attenuation of ischemic renal injury.
Since TxA2 is known to reduce renal blood flow [22], the
beneficial effect of uninephrectomy on ischemic injury may be
mediated through an increase in RBF in the Sham-Nx group.
Fernandez-Repollet and Finn [2, 31 suggested that the less
increase in preglomerular vascular resistance contributes to the
less reduction in C1,, in Nx animals. In the present study, however,
% recovery of RBF 48 hours after ischemia was rather lower in Nx
rats than in Sham-Nx animals. Fried et al [4], and Zager and
Baltes [6] also noticed no significant difference in % recovery of
RBF between Nx and Sham-Nx rats. Furthermore, several exper-
imental studies have demonstrated that the restoration of RBF
failed to provide a protective effect on ischemic renal injury
[23—25]. It is unlikely, therefore, that the less accumulation of
TxB2 may afford the protective effect of uninephrectomy through
well-maintained RBF. Since a TxA2 synthetase inhibitor, imida-
zole, was reported to increase medullary blood flow without
altering cortical blood flow [26], we cannot exclude the possibility
that less accumulation of TxB2 in Nx animals attenuated ischemic
renal injury through a preferential increase in medullary blood
flow. Following OKY-046 treatment, % recovery of RBF after
ischemia was significantly increased in Sham-Nx rats but not in Nx
animals, suggesting the contribution of TxB2 to ischemia-induced
decrease in RBF in Sham-Nx rats.
Since TxA2 is known to reduce glomerular planar surface area
and glomerular capillary ultrafiltration coefficient (Kf, hydraulic
conductivity multiplied by filtration area) [27], the uninephrec-
tomy-induced decrease in TxB2 content might have attenuated a
decrease in glomerular capillary filtration area and/or Kf. How-
ever, our previous study using scanning electron microscopy could
not find any significant difference in ischemia-induced alterations
of glomerular epithelium or endothelium between Nx and
Sham-Nx rats [5].
It is widely accepted that tubular obstruction due to casts and
transtubular back-leakage through necrotic tubules play major
pathophysiological roles in the development of ischemic acute
renal failure. In the present study, histological examination dis-
closed that tubular necrosis was more marked in Sham-Nx rats
than in Nx animals, as described previously [3—61. OKY-046
treatment abolished the difference in ischemia-induced tubular
necrosis between Nx and Sham-Nx rats as well as the difference in
C,,., 48 hours after RAO. These data suggested that the effect of
OKY-046 might be mediated through the attenuation of tubular
damage, and the beneficial effect of uninephrectomy on C,,, might
be ascribed, at least in part, to the difference in tubular damage
after ischemia.
In the present experiment, the renal 6-keto PGF1,.,/TxB2 ratio
was higher in Nx rats than in Sham-Nx animals before and after
renal ischemia. Kaufman et al [11] suggested that high 6-keto
PGF1,, to TxB2 ratio was a determinant to protect against acute
tubular necrosis. Klausner et al [28] also demonstrated that PG!2
analogue was effective against ischemic renal injury only if Tx was
inhibited. PGs may redistribute renal blood flow towards the
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vulnerable regions such as the corticomedullary junction and
outer medulla [29, 30]. A higher 6-keto PGF/TxB2 ratio in the
Nx group might have preserved blood perfusion in these areas,
resulting in the attenuation of tubular necrosis.
Intrarenal TxB2 may contribute directly to cell injury. Using
tubular epithelial cell (LLC-PK1 cell), Ueda et al [311 demon-
strated that TxA2 directly increased intracellular concentration of
calcium ion, which is known to mediate a variety of cell injuries. In
addition, a recent study demonstrated that TxA2 receptor block-
ade ameliorated the ischemia-induced decrease in ATP synthesis
and preserved the rise in calcium content in the cortical mito-
chondria [21].
The other possible mechanisms through which TxB2 mediates
ischemic renal injury are Tx-induced platelet aggregation and/or
polymorphonuclear leukocyte motility [14, 32, 33]. OKY-046
treatment is reported to prevent glomerular microthrombi in rats
with endotoxic shock [34]. The attenuation of ischemic myocardial
damage by a dual TxA2 synthetase inhibitor and TxA2 receptor
antagonist is known to be associated with reduced polymorpho-
nuclear leukocyte accumulation [35].
Recent investigations have suggested TxA2 may affect on
cellular proliferation within the kidney. For example, in cultured
cells, TxA2 agonists promote mitogenesis of fibroblast [36],
smooth muscle cell [37] and glomerular epithelial cell [38], but
inhibit growth factor-induced proliferation in mesangial cell [39].
Therefore, an alternative possibility remains that uninephrectomy
and/or OKY-046 treatment may influence on postischemic tubu-
lar epithelial regeneration. To address this possibility, PCNA
expression was evaluated in postischemic formalin-fixed kidneys
48 hours after renal ischemia. PCNA, a DNA polymerase b-asso-
ciated protein, is used as a sensitive marker for tubular cell
proliferation, since PCNA staining reflects late G1, S, and early
G2 phases of the cell cycle in formalin-fixed tissues [40]. PCNA
expression was increased in tubular cell nuclei following renal
ischemia [41—43] or unilateral nephrectomy [44]. Witzgall et al
[42] demonstrated that PCNA staining in S3 segment was positive
within 24 hours after ischemia and was maximum at 48 hours. All
of PCNA staining cells were negative for clusterin staining, a
marker for cell injury. In the present work, PCNA positive nuclei
was greater in Nx rats. OKY-046 treatment increased PCNA
positive nuclei in Sham-Nx rats but not in Nx animals. Since
PCNA is expressed in nuclei during cell proliferation and/or DNA
repair [45], these data suggest that uninephrectomy might pro-
mote tubular recovery more promptly through the less production
of intrarenal TxB2.
In summary, the present study demonstrated that contralateral
nephrectomy attenuated the ischemia-induced increase in renal
TxB2 content. A TxA2 synthetase inhibitor, OKY-046, signifi-
cantly attenuated the ischemia-induced decrease in GFR and
tubular damage in Sham-Nx rats, but not Nx animals. Under the
treatment with OKY-046, the ischemia-induced decrease in GFR
and tubular damage were the same between Nx and Sham-Nx rats.
OKY-046 also increased PCNA expression in the outer medulla in
Sham-Nx group. These data suggest that a reduction in the renal
production of intrarenal TxB2 contributes to the effect of prior
uninephrectomy to attenuate ischemic renal injury.
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